Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

22 Background: Androgen deprivation therapy (ADT) is considered standard of care in the treatment of metastatic prostate cancer (mPC). Over the past ten years, the approval of novel androgen receptor-axis-targeted therapies has changed the treatment landscape of mPC. All these novel therapies have only been approved for use in addition to ADT. Despite these new therapeutic advances, it remains...

  • 123456 Profile photo of Madelyn

    While we talk about combining 2+ therapies, still data suggesting some men with metastatic prostate cancer are not started on ADT at all. what do you think are the barriers?